Trigemina, a pharmaceutical maker working on therapies for acute and chronic pain, has brought in $305,000 of an anticipated $999,000 round of equity and rights, according to a filing with the SEC. Based in Mountain View, Calif., the company is backed by grants from the National Institutes of Health, as well as equity from private sources.